Denali Therapeutics Inc. Variable Lease, Cost
Denali Therapeutics Inc. (DNLI) reported Variable Lease, Cost of $1.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-06
- Denali Therapeutics Inc. variable lease, cost for the quarter ending 2026-06-30 was $1.79M, a 33.93% increase year-over-year.
- Denali Therapeutics Inc. variable lease, cost for the quarter ending 2026-03-31 was $1.04M, a 23.13% decline year-over-year.
- Denali Therapeutics Inc. variable lease, cost for the quarter ending 2025-12-31 was $1.71M, a 46.44% increase year-over-year.
- Denali Therapeutics Inc. variable lease, cost for the quarter ending 2025-09-30 was $1.50M, a 6.25% decline year-over-year.
- Denali Therapeutics Inc. variable lease, cost for fiscal 2025 was $5.81M, a 14.63% increase from fiscal 2024.
- Denali Therapeutics Inc. variable lease, cost for fiscal 2024 was $5.07M, a 13.62% increase from fiscal 2023.
- Denali Therapeutics Inc. variable lease, cost for fiscal 2023 was $4.46M, a 11.45% increase from fiscal 2022.
- Denali Therapeutics Inc. variable lease, cost for fiscal 2022 was $4.00M.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 3 month as first filed | Variable Lease, Cost 6 month | Variable Lease, Cost 6 month as first filed | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month | Variable Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.79M 10-Q · filed 2026-08-06 | $2.83M 10-Q · filed 2026-08-06 | $4.54M derived: sum of 3 quarters · filed 2026-08-06 | $6.04M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $1.04M 10-Q · filed 2026-05-07 | $2.75M derived: sum of 2 quarters · filed 2026-05-07 | $4.25M derived: sum of 3 quarters · filed 2026-05-07 | $5.58M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.21M derived: sum of 2 quarters · filed 2026-02-26 | $4.54M derived: sum of 3 quarters · filed 2026-08-06 | $5.81M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $1.50M 10-Q · filed 2025-11-06 | $2.84M derived: sum of 2 quarters · filed 2026-08-06 | $4.10M 10-Q · filed 2025-11-06 | $5.36M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $1.34M 10-Q · filed 2026-08-06 | $1.20M 10-Q · filed 2025-08-11 | $2.69M 10-Q · filed 2026-08-06 | $2.50M 10-Q · filed 2025-08-11 | $3.86M derived: sum of 3 quarters · filed 2026-08-06 | $5.46M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $1.35M 10-Q · filed 2026-05-07 | $1.40M 10-Q · filed 2025-05-06 | $2.52M derived: sum of 2 quarters · filed 2026-05-07 | $4.12M derived: sum of 3 quarters · filed 2026-05-07 | $5.32M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.77M derived: sum of 2 quarters · filed 2026-02-26 | $3.96M derived: sum of 3 quarters · filed 2026-02-26 | $5.07M 10-K · filed 2026-02-26 | $5.10M 10-K · filed 2025-02-27 | ||
| 2024-09-30 | $1.60M 10-Q · filed 2025-11-06 | $2.80M derived: sum of 2 quarters · filed 2025-11-06 | $3.90M 10-Q · filed 2025-11-06 | $4.86M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $1.20M 10-Q · filed 2025-08-11 | $2.30M 10-Q · filed 2025-08-11 | $3.26M derived: sum of 3 quarters · filed 2026-02-26 | $4.56M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $900.00K 10-Q · filed 2025-05-06 | $2.06M derived: sum of 2 quarters · filed 2026-02-26 | $3.36M derived: sum of 3 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.46M derived: sum of 2 quarters · filed 2026-02-26 | $4.46M 10-K · filed 2026-02-26 | $4.40M 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $1.30M 10-Q · filed 2024-11-06 | $3.30M 10-Q · filed 2024-11-06 | |||||
| 2022-12-31 | $4.00M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |